Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFRAN: Type I Interferon Excess in Autoimmune Diseases
NCT07837986Not yet recruiting
- Sponsor
- Hospices Civils de Lyon
- Start
- Dec 2026
- Primary completion
- Jan 2033
- Countries
- 1
01
Overview
Trial (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Type I Interferon gene signature score at Month 12. Planned start Dec 2026; status: not yet recruiting.
Beyond the preview
Go deeper on NCT07837986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07837986.